Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 11/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 3/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5210434 | 0.93 | HTR1F (0.65) | HTR1FKMT2AMEN1CCR3 | |
| SCHEMBL5211871 | 0.90 | HTR1F (0.64) | HTR1FKMT2AMEN1CCR3EPHX2 | |
| SCHEMBL27472240 | 0.90 | HTR1F (0.61) | HTR1FKMT2AMEN1TP53 | |
| Formic Acid SCHEMBL5209726 | 0.89 | HTR1F (0.58) | HTR1FKMT2AMEN1CCR3EPHX2 | |
| SCHEMBL5213054 | 0.88 | HTR1F (0.65) | HTR1FKMT2AMEN1CCR3EPHX2 | |
| SCHEMBL5209311 | 0.88 | HTR1F (0.61) | HTR1FKMT2AMEN1TP53 | |
| SCHEMBL5212023 | 0.86 | HTR1F (0.67) | HTR1FKMT2AMEN1EPHX2 | |
| SCHEMBL5211786 | 0.85 | HTR1F (0.73) | HTR1FKMT2AMEN1EPHX2 | |
| SCHEMBL5210595 | 0.85 | HTR1F (0.60) | HTR1FKMT2AMEN1CCR3TP53 | |
| SCHEMBL5212582 | 0.85 | HTR1F (0.60) | HTR1FKMT2AMEN1CCR3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1153013-B1 | 5-HT1F AGONISTS | LILLY CO ELI (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | POZEN INC. (US) | 2006-08-10 | — | — | US | disclosed |
| US-6777428-B1 | INHIBIT PEPTIDE EXTRAVASATION DUE TO STIMULATION OF THE TRIGEMINAL GANGLIA, AND ARE THEREFORE USEFUL FOR THE TREATMENT OF MIGRAINE AND ASSOCIATED DISORDERS | ELI LILLY AND COMPANY | 2004-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178349-A1 | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID | HTR1F, HTR1A, HTR1E | HTR1F 1/4885KMT2A 3859/4885MEN1 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.